About Tumor necrosis factor ligand superfamily member 13B
Tumor necrosis factor ligand superfamily member 13B (TNFSF13B) is a protein
from Homo sapiens identified by UniProt accession
Q9Y275, 285 residues long.
MolForge cross-references it against 0 known binders and
714 disease associations.
Target properties
| Protein name | Tumor necrosis factor ligand superfamily member 13B |
| UniProt accession | Q9Y275 |
| Gene | TNFSF13B |
| Organism | Homo sapiens |
| Length | 285 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (714)
Diseases linked to this target (Open Targets).
- systemic lupus erythematosus · score 0.60
- monocyte count · score 0.53
- platelet count · score 0.50
- neutrophil count · score 0.49
- lupus nephritis · score 0.49
- leukocyte count · score 0.48
- monocyte percentage of leukocytes · score 0.47
- platelet crit · score 0.47
- myeloid white cell count · score 0.47
- platelet component distribution width · score 0.46
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9Y275-F1 | alphafold | PREDICTED | 78.36 | — |
Amino-acid sequence (285 residues)
MDDSTEREQS RLTSCLKKRE EMKLKECVSI LPRKESPSVR SSKDGKLLAA TLLLALLSCC LTVVSFYQVA ALQGDLASLR AELQGHHAEK LPAGAGAPKA GLEEAPAVTA GLKIFEPPAP GEGNSSQNSR NKRAVQGPEE TVTQDCLQLI ADSETPTIQK GSYTFVPWLL SFKRGSALEE KENKILVKET GYFFIYGQVL YTDKTYAMGH LIQRKKVHVF GDELSLVTLF RCIQNMPETL PNNSCYSAGI AKLEEGDELQ LAIPRENAQI SLDGDVTFFG ALKLL
Explore Tumor necrosis factor ligand superfamily member 13B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets